Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.47 |
| ▸ | USP14 | P54578 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7586943 | 0.86 | CTSK (0.51) | CTSKKCNA3USP14HSD11B1CYP2C9 | |
| SCHEMBL7578299 | 0.83 | CTSK (0.48) | CTSKKCNA3USP14HSD11B1CYP2C9 | |
| SCHEMBL2693344 | 0.82 | KCNA3 (0.54) | CTSKKCNA3USP14HSD11B1CYP2C9 | |
| SCHEMBL12228102 | 0.81 | CTSK (0.51) | CTSKKCNA3USP14HSD11B1CYP2C9 | |
| SCHEMBL7587426 | 0.81 | CTSK (0.46) | CTSKKCNA3USP14HSD11B1CYP2C9 | |
| SCHEMBL21098058 | 0.80 | CTSK (0.57) | CTSKKCNA3HSD11B1CYP2C9DRD2 | |
| SCHEMBL21098084 | 0.80 | CTSK (0.57) | CTSKKCNA3HSD11B1CYP2C9DRD2 | |
| SCHEMBL21063443 | 0.80 | CTSK (0.57) | CTSKKCNA3HSD11B1CYP2C9DRD2 | |
| SCHEMBL1063091 | 0.80 | EPHX1 (0.55) | CTSKHSD11B1CYP2C9BTKCA1 | |
| SCHEMBL15373110 | 0.80 | KCNA3 (0.52) | CTSKKCNA3USP14HSD11B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | PKD1, REN, CYP11B1 | CTSK 2841/4885KCNA3 2714/4885USP14 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.